Lysophosphatidic Acid (LPA) Receptor Signaling

Lysophospholipid Receptors: Signaling and Biochemistry

Volumn , Issue , 2013, Pages 1-39

  Mirendil, Hope ^a   Lin, Mu En ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

GPCRs for LPA and S1P; LPA metabolism, and receptors; LPA receptor signaling, and ATX; LPA, agonists antagonists; LPAs as bioactive lipids

Indexed keywords

EID: 84886531537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118531426.ch1     Document Type: Chapter

References (260)

1. Moolenaar WH. 1999. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253:230-238.
2. Tigyi G, Parrill AL. 2003. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42:498-526.
3. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. 2010. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
4. Ishii I, Fukushima N, Ye X, Chun J. 2004. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321-354.
5. Dealvarez RR, Goodell BW. 1964. Serum lipid partitions and fatty acid composition (using gas chromatography) in gynecological cancer. Am J Obstet Gynecol 88:1039-1062.
6. Coleman R, Bell RM. 1978. Evidence that biosynthesis of phosphatidylethanolamine, phosphatidylcholine, and triacylglycerol occurs on the cytoplasmic side of microsomal vesicles. J Cell Biol 76:245-253.
7. Vogt W. 1963. Pharamacologically active acidic phospholipids and glycolipids. Biochem Pharmacol 12:415-420.
8. Sen S, Smeby RR, Bumpus FM. 1968. Antihypertensive effect of an isolated phospholipid. Am J Physiol 214:337-341.
9. Tokumura A, Fukuzawa K, Tsukatani H. 1978. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids 13:572-574.
10. Blankley CJ, Kaplan HR. 1984. Biologically-active phospholipids as potential cardiovascular drugs. Drug Dev Res 4:351.
11. Porn MI, Akerman KE, Slotte JP. 1991. High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fibroblasts. Biochem J 279(Pt 1):29-33.
12. Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. 1979. Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux. Am J Pathol 96:423-438.
13. Snyder F. 1990. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol 259:C697-C708.
14. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH. 1989. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59:45-54.
15. Hecht JH, Weiner JA, Post SR, Chun J. 1996. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135:1071-1083.
16. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. 2010. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 62:579-587.
17. An S, Bleu T, Hallmark OG, Goetzl EJ. 1998. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273:7906-7910.
18. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, et al. 1999. Molecular cloning and characterization of a novel human Gprotein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 274: 27776-27785.
19. An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, Goetzl EJ. 1997. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett 417:279-282.
20. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. 2001. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41:507-534.
21. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
22. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
23. Noguchi K, Ishii S, Shimizu T. 2003. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278:25600-25606.
24. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, et al. 2006. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318:619-628.
25. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. 2006. GPR92 as a new G12/13-and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281:23589-23597.
26. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, et al. 2009. Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6. J Biol Chem 284:17731-17741.
27. Pasternack SM, von Kügelgen I, Aboud KA, Lee YA, Rüschendorf F, Voss K, et al. 2008. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 40:329-334.
28. Makide K, Kitamura H, Sato Y, Okutani M, Aoki J. 2009. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 89:135-139.
29. Kano K, Arima N, Ohgami M, Aoki J. 2008. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem 15: 2122-2131.
30. Okudaira S, Yukiura H, Aoki J. 2010. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92:698-706.
31. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, et al. 2002. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 277:48737-48744.
32. Aoki J. 2004. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 15:477-489.
33. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A, et al. 1999. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta 1440:194-204.
34. Sano T, Baker D, Virag T, Wada A, Yatomi Y, Kobayashi T, et al. 2002. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 277:21197-21206.
35. Aoki J, Inoue A, Okudaira S. 2008. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781:513-518.
36. Tokumura A, Harada K, Fukuzawa K, Tsukatani H. 1986. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim Biophys Acta 875:31-38.
37. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158:227-233.
38. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, et al. 2002. Identification of human plasma lysophospholipase D, a lysophosphatidic acidproducing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277:39436-39442.
39. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. 2005. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 169:801-811.
40. Pagès C, Simon M, Valet P, Saulnier-Blache JS. 2001. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64:1-10.
41. Bräuer AU, Savaskan NE, Kühn H, Prehn S, Ninnemann O, Nitsch R. 2003. A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci 6:572-578.
42. Smyth SS, Cheng HY, Miriyala S, Panchatcharam M, Morris AJ. 2008. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 1781:563-570.
43. Aaltonen N, Laitinen JT, Lehtonen M. 2010. Quantification of lysophosphatidic acids in rat brain tissue by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1145-1152.
44. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H, et al. 2008. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem 45: 364-368.
45. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, et al. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 41:616-623.
46. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. 1992. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267:2524-2529.
47. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. 2000. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 35:393-432.
48. Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, et al. 1996. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 271:24408-24412.
49. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, et al. 2004. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279:17634-17639.
50. Nakamura K, Ohkawa R, Okubo S, Yokota H, Ikeda H, Yatomi Y, et al. 2009. Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clin Chim Acta 405:160-162.
51. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, Otani K, et al. 2008. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol 173:1566-1576.
52. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. 2008. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9:415-423.
53. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015-5022.
54. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281:25822-25830.
55. Koike S, Keino-Masu K, Masu M. 2010. Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochem Biophys Res Commun 400:66.
56. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. 1995. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol 268: H2048-H2055.
57. Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF. 1997. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med 129:208-216.
58. Lee H, Goetzl EJ, An S. 2000. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am J Physiol Cell Physiol 278: C612-C618.
59. Lin CH, Lu J, Lee H. 2011. Interleukin-1beta expression is required for lysophosphatidic Acid-induced lymphangiogenesis in human umbilical vein endothelial cells. Int J Inflam 2011:351010.
60. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. 2005. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146:3387-3400.
61. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, et al. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 96:6931-6936.
62. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. 1993. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 291:677-680.
63. Anliker B, Chun J. 2004. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 15:457-465.
64. Pilquil C, Dewald J, Cherney A, Gorshkova I, Tigyi G, English D, et al. 2006. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. J Biol Chem 281:38418-38429.
65. Siess W. 2003. Athero-and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 1582:204-215.
66. Van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. 2000. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 20:E127-E133.
67. Lin CI, Chen CN, Chen JH, Lee H. 2006. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem 99:1216-1232.
68. Palmetshofer A, Robson SC, Nehls V. 1999. Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells. Thromb Haemost 82:1532-1537.
69. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, et al. 1999. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 79: 1227-1235.
70. Chang CL, Hsu HY, Lin HY, Chiang W, Lee H. 2008. Lysophosphatidic acidinduced oxidized low-density lipoprotein uptake is class A scavenger receptordependent in macrophages. Prostaglandins Other Lipid Mediat 87:20-25.
71. Chang CL, Lin ME, Hsu HY, Yao CL, Hwang SM, Pan CY, et al. 2008. Lysophosphatidic acid-induced interleukin-1 beta expression is mediated through Gi/Rho and the generation of reactive oxygen species in macrophages. J Biomed Sci 15: 357-363.
72. Neidlinger NA, Larkin SK, Bhagat A, Victorino GP, Kuypers FA. 2006. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem 281:775-781.
73. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, et al. 2003. Subtypeselective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108:741-747.
74. Li ZG, Yu ZC, Wang DZ, Ju WP, Zhan X, Wu QZ, et al. 2008. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol Res 30:366-369.
75. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. 2001. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 33:1713-1717.
76. Chen J, Baydoun AR, Xu R, Deng L, Liu X, Zhu W, et al. 2008. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivationinduced apoptosis. Stem Cells 26:135-145.
77. Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, Lynch KR. 2003. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemiareperfusion injury. Am J Physiol Renal Physiol 285:F565-F574.
78. Savitz SI, Dhallu MS, Malhotra S, Mammis A, Ocava LC, Rosenbaum PS, et al. 2006. EDG receptors as a potential therapeutic target in retinal ischemiareperfusion injury. Brain Res 1118:168-175.
79. Brault S, Gobeil F Jr, Fortier A, Honoré JC, Joyal JS, Sapieha PS, et al. 2007. Lysophosphatidic acid induces endothelial cell death by modulating the redox environment. Am J Physiol Regul Integr Comp Physiol 292:R1174-R1183.
80. Herr KJ, Herr DR, Lee CW, Noguchi K, Chun J. 2011. Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling. Proc Natl Acad Sci U S A 108:15444-15449.
81. Li S, Zhang J. 2009. Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells. Biochem Biophys Res Commun 378:264-268.
82. Nam JH, Shin DH, Min JE, Ye SK, Jeon JH, Kim SJ. 2010. Ca2+ signaling induced by sphingosine 1-phosphate and lysophosphatidic acid in mouse B cells. Mol Cells 29:85-91.
83. Yin Z, Carbone LD, Gotoh M, Postlethwaite A, Bolen AL, Tigyi GJ, et al. 2010. Lysophosphatidic acid-activated Cl-current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) 49:2290-2297.
84. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, et al. 2009. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine-1-phosphate in systemic sclerosis. Int J Med Sci 6:168-176.
85. Mototani H, Iida A, Nakajima M, Furuichi T, Miyamoto Y, Tsunoda T, et al. 2008. A functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese. Hum Mol Genet 17:1790-1797.
86. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, et al. 2008. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Mol Pharmacol 73:587-600.
87. Sturm A, Dignass AU. 2002. Modulation of gastrointestinal wound repair and inflammation by phospholipids. Biochim Biophys Acta 1582:282-288.
88. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. 2008. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14:45-54.
89. Lin ME, Herr DR, Chun J. 2010. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91:130-138.
90. Tigyi G. 2010. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161:241-270.
91. Mutoh T, Rivera R, Chun J. 2012. Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol 165:829-844.
92. Imamura F, Horai T, Mukai M, Shinkai K, Sawada M, Akedo H. 1993. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem Biophys Res Commun 193:497-503.
93. Xu Y, Fang XJ, Casey G, Mills GB. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309(Pt 3):933-940.
94. Rusovici R, Ghaleb A, Shim H, Yang VW, Yun CC. 2007. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta 1770: 1194-1203.
95. Yun CC, Sun H, Wang D, Rusovici R, Castleberry A, Hall RA, et al. 2005. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289:C2-C11.
96. Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, Hanibuchi M, et al. 2008. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. Cancer Sci 99:1603-1610.
97. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, et al. 2004. Overexpression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6:R640-R646.
98. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. 2007. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 1771:883-892.
99. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, et al. 2006. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281:17492-17500.
100. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, et al. 2006. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66: 3006-3014.
101. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, et al. 2004. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279:6595-6605.
102. Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S, et al. 1999. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 30:1027-1036.
103. Sedláková I, Vávrová J, Tošner J, Hanousek L. 2011. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumor Biol 32:311-316.
104. Nouh MA, Wu XX, Okazoe H, Tsunemori H, Haba R, Abou-Zeid AM, et al. 2009. Expression of Autotaxin and Acylglycerol kinase in prostate cancer: association with cancer development and progression. Cancer Sci 100:1631-1638.
105. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, et al. 2010. Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma. Mol Cancer 9:71.
106. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. 2009. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and aetastases. Cancer Cell 15:539-550.
107. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, et al. 2002. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19:603-608.
108. Yang Y, Lj M, Liu N, Tsao MS. 1999. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21:216-222.
109. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, et al. 2004. Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109:833-838.
110. Kazama S, Kitayama J, Aoki J, Mori K, Nagawa H. 2011. Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer. J Gastrointest Cancer 42:204-211.
111. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. 2009. Inhibition of autotaxin production or activity blocks lysophosphatidylcholineinduced migration of human breast cancer and melanoma cells. Mol Carcinog 48:801-809.
112. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, et al. 2009. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69:5441-5449.
113. Samadi N, Gaetano C, Goping IS, Brindley DN. 2008. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28:1028-1039.
114. David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, et al. 2010. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5:e9741.
115. Yamada T, Obo Y, Furukawa M, Hotta M, Yamasaki A, Honoki K, et al. 2009. Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun 378:424-427.
116. Tsujino M, Fujii M, Okabe K, Mori T, Fukushima N, Tsujiuchi T. 2010. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch 457:669-676.
117. Obo Y, Yamada T, Furukawa M, Hotta M, Honoki K, Fukushima N, et al. 2009. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res 660:47-50.
118. Okabe K, Hayashi M, Fujii M, Honoki K, Mori T, Fukushima N, et al. 2010. Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells. Pathobiology 77:278-282.
119. Jeon ES, Lee IH, Heo SC, Shin SH, Choi YJ, Park JH, et al. 2010. Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim Biophys Acta 1801:1205-1213.
120. Jeon ES, Heo SC, Lee IH, Choi YJ, Park JH, Choi KU, et al. 2010. Ovarian cancerderived lysophosphatidic acid stimulates secretion of VEGF and stromal cellderived factor-1 alpha from human mesenchymal stem cells. Exp Mol Med 42:280-293.
121. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. 2001. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768.
122. Parrill AL, Baker DL. 2008. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 8:917-923.
123. Contos JJ, Chun J. 1998. Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. Genomics 51:364-378.
124. Valentine WJ, Fells JI, Perygin DH, Mujahid S, Yokoyama K, Fujiwara Y, et al. 2008. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J Biol Chem 283: 12175-12187.
125. Contos J, Ishii I, Chun J. 2000. Lysophosphatidic acid receptors. Mol Pharmacol 58:1188-1196.
126. Ye X. 2008. Lysophospholipid signaling in the function and pathology of the reproductive system. Hum Reprod Update 14:519-536.
127. Ohuchi H, Hamada A, Matsuda H, Takagi A, Tanaka M, Aoki J, et al. 2008. Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev Dyn 237:3280-3294.
128. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. 2000. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 97:13384-13389.
129. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J. 2001. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 21:7069-7078.
130. Estivill-Torrús G, Llebrez-Zayas P, Matas-Rico E, Santín L, Pedraza C, De Diego I, et al. 2008. Absence of LPA1 signaling results in defective cortical development. Cereb Cortex 18:938-950.
131. Matas-Rico E, García-Diaz B, Llebrez-Zayas P, López-Barroso D, Santín L, Pedraza C, et al. 2008. Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol Cell Neurosci 39:342-355.
132. Harrison SM, Reavill C, Brown G, Brown JT, Cluderay JE, Crook B, et al. 2003. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 24:1170-1179.
133. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J. 2003. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 6:1292-1299.
134. Campbell DS, Holt CE. 2001. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32: 1013-1026.
135. Fukushima N, Weiner JA, Chun J. 2000. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol 228:6-18.
136. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, et al. 2003. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 5:38-45.
137. Fukushima N, Weiner JA, Kaushal D, Contos JJ, Rehen SK, Kingsbury MA, et al. 2002. Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons. Mol Cell Neurosci 20:271-282.
138. Fukushima N, Kimura Y, Chun J. 1998. A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc Natl Acad Sci U S A 95:6151-6156.
139. Svetlov SI, Ignatova TN, Wang KK, Hayes RL, English D, Kukekov VG. 2004. Lysophosphatidic acid induces clonal generation of mouse neurospheres via proliferation of Sca-1-and AC133-positive neural progenitors. Stem Cells Dev 13: 685-693.
140. Lloyd B, Tao Q, Lang S, Wylie C. 2005. Lysophosphatidic acid signaling controls cortical actin assembly and cytoarchitecture in Xenopus embryos. Development 132:805-816.
141. Jalink K, Eichholtz T, Postma FR, van Corven EJ, Moolenaar WH. 1993. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ 4:247-255.
142. Tigyi G, Fischer DJ, Sebök A, Yang C, Dyer DL, Miledi R. 1996. Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. J Neurochem 66:537-548.
143. Holtsberg FW, Steiner MR, Bruce-Keller AJ, Keller JN, Mattson MP, Moyers JC, et al. 1998. Lysophosphatidic acid and apoptosis of nerve growth factordifferentiated PC12 cells. J Neurosci Res 53:685-696.
144. Zheng ZQ, Fang XJ, Qiao JT. 2004. Dual action of lysophosphatidic acid in cultured cortical neurons: survival and apoptogenic. Sheng Li Xue Bao 56:163-171.
145. Shano S, Moriyama R, Chun J, Fukushima N. 2008. Lysophosphatidic acid stimulates astrocyte proliferation through LPA1. Neurochem Int 52:216-220.
146. Manning TJ Jr, Sontheimer H. 1996. Bovine serum albumin and lysophosphatidic acid stimulate calcium mobilization and reversal of cAMP-induced stellation in rat spinal cord astrocytes. Glia 20:163-172.
147. Suidan HS, Nobes CD, Hall A, Monard D. 1997. Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia 21:244-252.
148. Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, et al. 2003. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64:1199-1209.
149. Noguchi K, Herr D, Mutoh T, Chun J. 2009. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9:15-23.
150. Sato K, Horiuchi Y, Jin Y, Malchinkhuu E, Komachi M, Kondo T, et al. 2011. Unmasking of LPA(1) receptor-mediated migration response to lysophosphatidic acid by interleukin-1beta-induced attenuation of Rho signaling pathways in rat astrocytes. J Neurochem 117:164-174.
151. Spohr TC, Choi JW, Gardell SE, Herr DR, Rehen SK, Gomes FC, et al. 2008. Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J Biol Chem 283:7470-7479.
152. Weiner JA, Hecht JH, Chun J. 1998. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 398:587-598.
153. Allard J, Barrón S, Diaz J, Lubetzki C, Zalc B, Schwartz JC, et al. 1998. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur J Neurosci 10:1045-1053.
154. Yu N, Lariosa-Willingham KD, Lin FF, Webb M, Rao TS. 2004. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45:17-27.
155. Stankoff B, Barron S, Allard J, Barbin G, Noël F, Aigrot MS, et al. 2002. Oligodendroglial expression of Edg-2 receptor: developmental analysis and pharmacological responses to lysophosphatidic acid. Mol Cell Neurosci 20:415-428.
156. Dawson J, Hotchin N, Lax S, Rumsby M. 2003. Lysophosphatidic acid induces process retraction in CG-4 line oligodendrocytes and oligodendrocyte precursor cells but not in differentiated oligodendrocytes. J Neurochem 87:947-957.
157. Nogaroli L, Yuelling LM, Dennis J, Gorse K, Payne SG, Fuss B. 2009. Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes. Neurochem Res 34:182-193.
158. Kobashi H, Yaoi T, Oda R, Okajima S, Fujiwara H, Kubo T, et al. 2006. Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell rt-PCR and in situ hybridization. Acta Histochem Cytochem 39:55-60.
159. Weiner JA, Chun J. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci U S A 96:5233-5238.
160. Li Y, Gonzalez MI, Meinkoth JL, Field J, Kazanietz MG, Tennekoon GI. 2003. Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells. J Biol Chem 278:9585-9591.
161. Renbäck K, Inoue M, Yoshida A, Nyberg F, Ueda H. 2000. Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res Mol Brain Res 75:350-354.
162. Renback K, Inoue M, Ueda H. 1999. Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci Lett 270:59-61.
163. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. 2004. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10: 712-718.
164. Fujita R, Kiguchi N, Ueda H. 2007. LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 50:351-355.
165. Inoue M, Ma L, Aoki J, Chun J, Ueda H. 2008. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 4:6.
166. Inoue M, Ma L, Aoki J, Ueda H. 2008. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J Neurochem 107:1556-1565.
167. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H. 2008. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152:296-298.
168. Cannon M, Jones PB, Murray RM. 2002. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159:1080-1092.
169. Hultman CM, Sparén P, Takei N, Murray RM, Cnattingius S. 1999. Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. BMJ 318:421-426.
170. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. 2007. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 97:51-59.
171. Brimacombe M, Ming X, Lamendola M. 2007. Prenatal and birth complications in autism. Matern Child Health J 11:73-79.
172. Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, et al. 2011. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl Med 3: 99ra87.
173. Roberts C, Winter P, Shilliam CS, Hughes ZA, Langmead C, Maycox PR, et al. 2005. Neurochemical changes in LPA1 receptor deficient mice-a putative model of schizophrenia. Neurochem Res 30:371-377.
174. Musazzi L, Di Daniel E, Maycox P, Racagni G, Popoli M. 2010. Abnormalities in alpha/beta-CaMKII and related mechanisms suggest synaptic dysfunction in hippocampus of LPA1 receptor knockout mice. Int J Neuropsychopharmacol 14: 941-953.
175. Cunningham MO, Hunt J, Middleton S, LeBeau FE, Gillies MJ, Davies CH, et al. 2006. Region-specific reduction in entorhinal gamma oscillations and parvalbuminimmunoreactive neurons in animal models of psychiatric illness. J Neurosci 26:2767-2776.
176. Santin LJ, Bilbao A, Pedraza C, Matas-Rico E, López-Barroso D, Castilla-Ortega E, et al. 2009. Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav 8:772-784.
177. Castilla-Ortega E, Sánchez-López J, Hoyo-Becerra C, Matas-Rico E, Zambrana-Infantes E, Chun J, et al. 2010. Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor. Neurobiol Learn Mem 94:73-82.
178. Ong WY, Farooqui T, Farooqui AA. 2010. Involvement of cytosolic phospholipase A2, calcium independent phospholipase A2 and plasmalogen selective phospholipase A2 in neurodegenerative and neuropsychiatric conditions. Curr Med Chem 17:2746-2763.
179. Dash PK, Orsi SA, Moody M, Moore AN. 2004. A role for hippocampal Rho-ROCK pathway in long-term spatial memory. Biochem Biophys Res Commun 322:893-898.
180. Valet P, Pagès C, Jeanneton O, Daviaud D, Barbe P, Record M, et al. 1998. Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J Clin Invest 101:1431-1438.
181. Nobusue H, Kondo D, Yamamoto M, Kano K. 2010. Effects of lysophosphatidic acid on the in vitro proliferation and differentiation of a novel porcine preadipocyte cell line. Comp Biochem Physiol B Biochem Mol Biol 157:401-407.
182. Ferry G, Tellier E, Try A, Grés S, Naime I, Simon MF, et al. 2003. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278:18162-18169.
183. Boucher J, Quilliot D, Pradères JP, Simon MF, Grès S, Guigné C, et al. 2005. Potential involvement of adipocyte insulin resistance in obesity-associated upregulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48:569-577.
184. Yea K, Kim J, Lim S, Park HS, Park KS, Suh PG, et al. 2008. Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J Mol Med 86:211-220.
185. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. 2002. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation-and chemotherapy-induced apoptosis. Gastroenterology 123:206-216.
186. Holmström TE, Mattsson CL, Wang Y, Iakovleva I, Petrovic N, Nedergaard J. 2010. Non-transactivational, dual pathways for LPA-induced Erk1/2 activation in primary cultures of brown pre-adipocytes. Exp Cell Res 316:2664-2675.
187. Simon MF, Daviaud D, Pradère JP, Grès S, Guigné C, Wabitsch M, et al. 2005. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280:14656-14662.
188. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, et al. 2008. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res 103:662-670.
189. Dusaulcy R, Daviaud D, Pradère JP, Grès S, Valet P, Saulnier-Blache JS. 2009. Altered food consumption in mice lacking lysophosphatidic acid receptor-1. J Physiol Biochem 65:345-350.
190. Pradère JP, Klein J, Grès S, Guigné C, Neau E, Valet P, et al. 2007. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18:3110-3118.
191. Kim J, Keys JR, Eckhart AD. 2006. Vascular smooth muscle migration and proliferation in response to lysophosphatidic acid (LPA) is mediated by LPA receptors coupling to Gq. Cell Signal 18:1695-1701.
192. Pradère JP, Gonzalez J, Klein J, Valet P, Grès S, Salant D, et al. 2008. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 1781:582-587.
193. Ikeda H, Yatomi Y, Yanase M, Satoh H, Nishihara A, Kawabata M, et al. 1998. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun 248:436-440.
194. Wu J, Zern MA. 2000. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35:665-675.
195. Contos JJ, Chun J. 2000. Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics 64:155-169.
196. Zheng Y, Kong Y, Goetzl EJ. 2001. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 166:2317-2322.
197. Goetzl EJ, Kong Y, Mei B. 1999. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162:2049-2056.
198. Zheng Y, Voice JK, Kong Y, Goetzl EJ. 2000. Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J 14:2387-2389.
199. Lai YJ, Chen CS, Lin WC, Lin FT. 2005. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol 25:5859-5868.
200. Lai YJ, Lin WC, Lin FT. 2007. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J Biol Chem 282:24381-24387.
201. Lin FT, Lai YJ. 2008. Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions. Biochim Biophys Acta 1781:558-562.
202. Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, et al. 2009. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 30:457-465.
203. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M, et al. 2009. Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell 138:1222-1235.
204. Sarker MH, Hu DE, Fraser PA. 2010. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation 17:39-46.
205. Subramanian P, Karshovska E, Reinhard P, Megens RT, Zhou Z, Akhtar S, et al. 2010. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 107:96-105.
206. Lee SJ, Yun CC. 2010. Colorectal cancer cells-proliferation, survival and invasion by lysophosphatidic acid. Int J Biochem Cell Biol 42:1907-1910.
207. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, et al. 2004. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 84:1352-1362.
208. Jeong KJ, Park SY, Seo JH, Lee KB, Choi WS, Han JW, et al. 2008. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40:607-616.
209. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, et al. 2009. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol 112:215-223.
210. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, et al. 2003. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63:1706-1711.
211. Wang GL, Wen ZQ, Xu WP, Wang ZY, Du XL, Wang F. 2008. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells. Croat Med J 49:175-181.
212. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, et al. 2007. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 31:441-449.
213. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ. 2004. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23:122-129.
214. Shida D, Fang X, Kordula T, Takabe K, Lépine S, Alvarez SE, et al. 2008. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 68:6569-6577.
215. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX. 2009. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate 69:283-292.
216. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, et al. 2008. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630-1642.
217. Masiello LM, Fotos JS, Galileo DS, Karin NJ. 2006. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells. Bone 39:72-82.
218. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, et al. 2009. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7:1064-1077.
219. Shin KJ, Kim YL, Lee S, Kim DK, Ahn C, Chung J, et al. 2009. Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J Cancer Res Clin Oncol 135:45-52.
220. Panther E, Idzko M, Corinti S, Ferrari D, Herouy Y, Mockenhaupt M, et al. 2002. The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol 169:4129-4135.
221. Chen R, Roman J, Guo J, West E, McDyer J, Williams MA, et al. 2006. Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev 15:797-804.
222. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, et al. 2008. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283:21054-21064.
223. Goetzl EJ, Kong Y, Voice JK. 2000. Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol 164:4996-4999.
224. Rubenfeld J, Guo J, Sookrung N, Chen R, Chaicumpa W, Casolaro V, et al. 2006. Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am J Physiol Lung Cell Mol Physiol 290:L66-L74.
225. Chan LC, Peters W, Xu Y, Chun J, Farese RV Jr, Cases S. 2007. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J Leukoc Biol 82:1193-1200.
226. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D, et al. 2000. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57:753-759.
227. Ishii I, Contos JJ, Fukushima N, Chun J. 2000. Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 58:895-902.
228. Sonoda H, Aoki J, Hiramatsu T, Ishida M, Bandoh K, Nagai Y, et al. 2002. A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem 277:34254-34263.
229. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, et al. 2005. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435:104-108.
230. Budnik LT, Mukhopadhyay AK. 2002. Lysophosphatidic acid and its role in reproduction. Biol Reprod 66:859-865.
231. Iwasawa Y, Fujii T, Nagamatsu T, Kawana K, Okudaira S, Miura S, et al. 2009. Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. Am J Reprod Immunol 62:90-95.
232. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M, Fukuzawa K. 2002. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. Biol Reprod 67:1386-1392.
233. Hama K, Aoki J, Bandoh K, Inoue A, Endo T, Amano T, et al. 2006. Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci 79:1736-1740.
234. Hama K, Aoki J, Inoue A, Endo T, Amano T, Motoki R, et al. 2007. Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol Reprod 77:954-959.
235. Song H, Lim H, Paria BC, Matsumoto H, Swift LL, Morrow J, et al. 2002. Cytosolic phospholipase A2alpha is crucial (correction of A2alpha deficiency is crucial) for "on-time" embryo implantation that directs subsequent development. Development 129:2879-2889.
236. Mohamed OA, Jonnaert M, Labelle-Dumais C, Kuroda K, Clarke HJ, Dufort D. 2005. Uterine Wnt/beta-catenin signaling is required for implantation. Proc Natl Acad Sci U S A 102:8579-8584.
237. Ye X, Skinner MK, Kennedy G, Chun J. 2008. Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. Biol Reprod 79:328-336.
238. Garbi M, Rubinstein S, Lax Y, Breitbart H. 2000. Activation of protein kinase calpha in the lysophosphatidic acid-induced bovine sperm acrosome reaction and phospholipase D1 regulation. Biol Reprod 63:1271-1277.
239. Lee CW, Rivera R, Dubin AE, Chun J. 2007. LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 282:4310-4317.
240. Yanagida K, Ishii S, Hamano F, Noguchi K, Shimizu T. 2007. LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem 282:5814-5824.
241. Taghavi P, Verhoeven E, Jacobs JJ, Lambooij JP, Stortelers C, Tanger E, et al. 2008. In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 27:6806-6816.
242. Rhee HJ, Nam JS, Sun Y, Kim MJ, Choi HK, Han DH, et al. 2006. Lysophosphatidic acid stimulates cAMP accumulation and cAMP response element-binding protein phosphorylation in immortalized hippocampal progenitor cells. Neuroreport 17:523-526.
243. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, et al. 2008. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 19: 5435-5445.
244. Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F, et al. 2010. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 116:5060-5070.
245. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. 2010. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 109:794-800.
246. Mansell JP, Barbour M, Moore C, Nowghani M, Pabbruwe M, Sjostrom T, et al. 2010. The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces. Biomaterials 31:199-206.
247. Amisten S, Braun OO, Bengtsson A, Erlinge D. 2008. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122:47-57.
248. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, et al. 2009. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 284:17304-17319.
249. Lin S, Yeruva S, He P, Singh AK, Zhang H, Chen M, et al. 2010. Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 138:649-658.
250. Lee M, Choi S, Halldén G, Yo SJ, Schichnes D, Aponte GW. 2009. P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am J Physiol Gastrointest Liver Physiol 297:G641-G654.
251. Shimomura Y, Garzon MC, Kristal L, Shapiro L, Christiano AM. 2009. Autosomal recessive woolly hair with hypotrichosis caused by a novel homozygous mutation in the P2RY5 gene. Exp Dermatol 18:218-221.
252. Nahum S, Morice-Picard F, Taieb A, Sprecher E. 2011. Sprecher, A novel mutation in LPAR6 causes autosomal recessive hypotrichosis of the scalp. Clin Exp Dermatol 36:188-194.
253. Pasternack SM, von Kügelgen I, Müller M, Oji V, Traupe H, Sprecher E, et al. 2009. In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confirming the role of lipase H and lysophosphatidic acid in hair growth. J Invest Dermatol 129:2772-2776.
254. Shinkuma S, Akiyama M, Inoue A, Aoki J, Natsuga K, Nomura T, et al. 2010. Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PAPLA1alpha in autosomal recessive hypotrichosis. Hum Mutat 31:602-610.
255. Gajewiak J, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD. 2008. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid. Org Lett 10:1111-1114.
256. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, et al. 2007. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2:679-690.
257. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, et al. 2010. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 160:1699-1713.
258. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O. 2006. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643-9648.
259. Xu X, Yang G, Zhang H, Prestwich GD. 2009. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat 89:140-146.
260. Xu X, Prestwich GD. 2010. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116:1739-1750.